Payment overview · 2025
General Payments
$33.07
2 reported records · 2 companies
Healthcare provider profile · identity verified
Mark Douglas Ricaurte, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · COLUMBUS, OH · NPI 1669442091
Verified facts
What the public records show
CMS Open Payments records show Mark Douglas Ricaurte, M.D. received $33.07 in general payments during 2025 across 2 reported records.
Amgen Inc. accounted for 52.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.27 | 52.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.80 | 47.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $33.07 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
144 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1303 | 334 |
| Losartan Potassium | Losartan Potassium | 898 | 221 |
| Amlodipine Besylate | Amlodipine Besylate | 852 | 217 |
| Lisinopril | Lisinopril | 706 | 178 |
| Levothyroxine Sodium | Levothyroxine Sodium | 613 | 148 |
| Metoprolol Succinate | Metoprolol Succinate | 479 | 133 |
| Pantoprazole Sodium | Pantoprazole Sodium | 456 | 123 |
| Omeprazole | Omeprazole | 422 | 107 |
| Metformin Hcl | Metformin Hcl | 396 | 102 |
| Glimepiride | Glimepiride | 395 | 91 |
| Eliquis | Apixaban | 382 | 70 |
| Furosemide | Furosemide | 380 | 100 |
| Gabapentin | Gabapentin | 372 | 87 |
| Potassium Chloride | Potassium Chloride | 310 | 84 |
| Tamsulosin Hcl | Tamsulosin Hcl | 247 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 242 | 68 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 241 | 73 |
| Simvastatin | Simvastatin | 233 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 221 | 58 |
| Atenolol | Atenolol | 201 | 47 |
| Citalopram Hbr | Citalopram Hydrobromide | 197 | 47 |
| Klor-Con M20 | Potassium Chloride | 197 | 54 |
| Alendronate Sodium | Alendronate Sodium | 190 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 190 | 86 |
| Trazodone Hcl | Trazodone Hcl | 182 | 49 |
| Allopurinol | Allopurinol | 179 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 169 | 46 |
| Chlorthalidone | Chlorthalidone | 157 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 149 | 25 |
| Synthroid | Levothyroxine Sodium | 144 | 35 |
| Carvedilol | Carvedilol | 138 | 36 |
| Alprazolam | Alprazolam | 132 | 26 |
| Jardiance | Empagliflozin | 130 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 125 | 33 |
| Sertraline Hcl | Sertraline Hcl | 124 | 30 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 124 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 122 | 33 |
| Buspirone Hcl | Buspirone Hcl | 119 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 113 | 29 |
| Nifedipine Er | Nifedipine | 113 | 27 |
| Prednisone | Prednisone | 110 | 60 |
| Spironolactone | Spironolactone | 110 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 29 |
| Celecoxib | Celecoxib | 101 | 29 |
| Metformin Hcl Er | Metformin Hcl | 101 | 26 |
| Montelukast Sodium | Montelukast Sodium | 100 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 98 | 23 |
| Meloxicam | Meloxicam | 97 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 91 | 22 |
| Warfarin Sodium | Warfarin Sodium | 90 | 26 |
| Breo Ellipta | Fluticasone/Vilanterol | 89 | 15 |
| Donepezil Hcl | Donepezil Hcl | 88 | 18 |
| Pregabalin | Pregabalin | 87 | 14 |
| Famotidine | Famotidine | 86 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 85 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 85 | 72 |
| Finasteride | Finasteride | 84 | 26 |
| Tramadol Hcl | Tramadol Hcl | 84 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 83 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 80 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 80 | 44 |
| Ozempic | Semaglutide | 78 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 18 |
| Xarelto | Rivaroxaban | 74 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 72 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 17 |
| Bupropion Xl | Bupropion Hcl | 68 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 65 | 16 |
| Mirtazapine | Mirtazapine | 64 | 21 |
| Symbicort | Budesonide/Formoterol Fumarate | 63 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 16 |
| Lorazepam | Lorazepam | 55 | 15 |
| Meclizine Hcl | Meclizine Hcl | 55 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 55 | 14 |
| Testosterone | Testosterone | 54 | 11 |
| Methylprednisolone | Methylprednisolone | 49 | 38 |
| Cephalexin | Cephalexin | 47 | 34 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 46 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 44 | suppressed |
| Ondansetron Odt | Ondansetron | 43 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | 12 |
| Diazepam | Diazepam | 42 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 41 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 40 | 14 |
| Ramipril | Ramipril | 40 | suppressed |
| Azithromycin | Azithromycin | 39 | 33 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 33 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 11 |
| Ezetimibe | Ezetimibe | 37 | 12 |
| Valsartan | Valsartan | 37 | 12 |
| Ibuprofen | Ibuprofen | 35 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 34 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Naproxen | Naproxen | 34 | suppressed |
| Sotalol | Sotalol Hcl | 34 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 28 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Jantoven | Warfarin Sodium | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 24 |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 12 |
| Lovastatin | Lovastatin | 23 | suppressed |
| Nystatin | Nystatin | 23 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Clotrimazole | Clotrimazole | 22 | 15 |
| Colestipol Hcl | Colestipol Hcl | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 17 | suppressed |
| Daptomycin | Daptomycin | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Humulin R | Insulin Regular, Human | 15 | suppressed |
| Klor-Con M10 | Potassium Chloride | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 11 |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Trimethoprim | Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $33.07 · 2 records | Amgen Inc. | QULIPTA, REPATHA, UBRELVY | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error